Literature DB >> 1379147

Current recommendations for the treatment of Lyme disease.

L H Sigal1.   

Abstract

Lyme disease is a multisystem inflammatory disease caused by infection with Borrelia burgdorferi. Soon after the tick bite which transmits the infection, the pathognomonic skin rash erythema chronicum migrans occurs in 50 to 70% of patients, often with associated symptoms resembling a 'summer cold' or viral infection. Therapy for this stage of disease consists of 3 to 4 weeks of oral therapy. The agents currently used are: amoxicillin (500 mg 3 or 4 times daily) with or without probenecid 500 mg 3 times daily, doxycycline (100 mg twice daily), or tetracycline (500 mg 4 times daily). Longer duration therapy has never been evaluated and therefore is not currently indicated. Even patients with severe early manifestations of Lyme disease should be treated orally. Later features of Lyme disease include carditis and neurological disease, which can occur days to approximately 9 months after the onset of illness, and arthritis and neurological disease which can occur weeks to years after the onset of the illness. Treatment at this stage is with 2 to 3 weeks of intravenous antibiotics, currently cefotaxime (3 g every 12 hours), ceftriaxone (1 g every 12 hours or 2 g every day) and benzylpenicillin (14 g in divided doses). There is no evidence that longer duration therapy is indicated or more efficacious. The exception to this suggestion is the patient with isolated facial seventh cranial nerve palsy; if such a patient has no other signs or symptoms to suggest Lyme disease and has normal spinal fluid, oral therapy is usually sufficient, although some physicians will give concomitant corticosteroids to hasten the resolution of the palsy. Of major consequence to the practitioner and patient is the possibility that persistent symptoms (e.g. fibromyalgia) may be caused by a process which is no longer antibiotic-sensitive. Special care in the management of so-called 'chronic Lyme disease' is crucial lest the clinician prescribes prolonged or unending courses of antibiotics for such noninfectious problems.

Entities:  

Mesh:

Year:  1992        PMID: 1379147     DOI: 10.2165/00003495-199243050-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  95 in total

1.  Summary of the fourth international symposium on Lyme borreliosis.

Authors:  L H Sigal
Journal:  Arthritis Rheum       Date:  1991-03

Review 2.  Lyme disease, 1988: immunologic manifestations and possible immunopathogenetic mechanisms.

Authors:  L H Sigal
Journal:  Semin Arthritis Rheum       Date:  1989-02       Impact factor: 5.532

3.  Failure of tetracycline therapy in early Lyme disease.

Authors:  R J Dattwyler; J J Halperin
Journal:  Arthritis Rheum       Date:  1987-04

4.  Bilateral diffuse choroiditis and exudative retinal detachments with evidence of Lyme disease.

Authors:  A A Bialasiewicz; K W Ruprecht; G O Naumann; H Blenk
Journal:  Am J Ophthalmol       Date:  1988-04-15       Impact factor: 5.258

Review 5.  The global distribution of Lyme disease.

Authors:  G P Schmid
Journal:  Rev Infect Dis       Date:  1985 Jan-Feb

6.  Treatment of the early manifestations of Lyme disease.

Authors:  A C Steere; G J Hutchinson; D W Rahn; L H Sigal; J E Craft; E T DeSanna; S E Malawista
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

7.  Ocular Lyme borreliosis.

Authors:  K E Winward; J L Smith; W W Culbertson; A Paris-Hamelin
Journal:  Am J Ophthalmol       Date:  1989-12-15       Impact factor: 5.258

8.  Lyme disease presenting as heart block.

Authors:  R G Kishaba; E Weinhouse; M J Chusid; D B Nudel
Journal:  Clin Pediatr (Phila)       Date:  1988-06       Impact factor: 1.168

9.  Summary of the first 100 patients seen at a Lyme disease referral center.

Authors:  L H Sigal
Journal:  Am J Med       Date:  1990-06       Impact factor: 4.965

10.  The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis.

Authors:  A R Pachner; A C Steere
Journal:  Neurology       Date:  1985-01       Impact factor: 9.910

View more
  9 in total

Review 1.  Overdiagnosis and overtreatment of Lyme neuroborreliosis are preventable.

Authors:  A Prasad; D Sankar
Journal:  Postgrad Med J       Date:  1999-11       Impact factor: 2.401

2.  Long-term results in patients with Lyme arthritis following treatment with ceftriaxone.

Authors:  H Valesová; J Mailer; J Havlík; D Hulínská; J Hercogová
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

3.  Intracellular persistence of Borrelia burgdorferi in human synovial cells.

Authors:  H J Girschick; H I Huppertz; H Rüssmann; V Krenn; H Karch
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

4.  Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

Authors:  R K Straubinger; B A Summers; Y F Chang; M J Appel
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

Review 5.  Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.

Authors:  Göran Günther; Mats Haglund
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Ceftriaxone in the treatment of Lyme neuroborreliosis.

Authors:  H Rohácová; J Hancil; D Hulinská; H Mailer; J Havlík
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

7.  Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.

Authors:  K D Moody; R L Adams; S W Barthold
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Roxithromycin in the treatment of Lyme disease--update and perspectives.

Authors:  R Gasser; I Wendelin; E Reisinger; J Bergloff; B Feigl; I Schafhalter; B Eber; M Grisold; W Klein
Journal:  Infection       Date:  1995       Impact factor: 3.553

9.  Brief, recurrent, and spontaneous episodes of loss of consciousness in a healthy young male.

Authors:  Sherly Abraham; Sarath Reddy; Joseph Abboud; Krishnamurthy Jonnalagadda; Sasi K Ghanta; Vasantha Kondamudi
Journal:  Int Med Case Rep J       Date:  2010-07-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.